Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DCTHNYSE:GBSNASDAQ:ICCMNASDAQ:NVNO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$4.87+3.6%$4.47$2.25▼$7.99$119.44M0.53260,223 shs301,598 shsGBSGBS$2.74-2.1%$4.28$0.36▼$2.89$40.80M1.32955,325 shs57,865 shsICCMIceCure Medical$1.21-1.6%$1.27$0.52▼$1.57$56.12M0.73829,050 shs124,627 shsNVNOenVVeno Medical$4.62-3.3%$5.52$2.51▼$6.97$63.65M1.1762,939 shs70,703 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems+3.73%-1.62%+14.59%+22.98%-13.81%GBSGBS-2.14%-18.21%-34.76%+696.51%-9.87%ICCMIceCure Medical-1.63%-2.42%0.00%-3.20%-4.35%NVNOenVVeno Medical-3.35%-7.41%-19.51%+15.50%+1.09%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems2.9857 of 5 stars3.52.00.00.02.25.00.6GBSGBSN/AN/AN/AN/AN/AN/AN/AN/AICCMIceCure Medical1.5574 of 5 stars3.53.00.00.02.10.00.6NVNOenVVeno Medical0.2058 of 5 stars0.02.00.00.02.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems3.00Buy$18.50279.88% UpsideGBSGBSN/AN/AN/AN/AICCMIceCure Medical3.00Buy$2.95143.80% UpsideNVNOenVVeno MedicalN/AN/AN/AN/ACurrent Analyst RatingsLatest DCTH, GBS, NVNO, and ICCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.004/4/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.003/27/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.003/20/2024ICCMIceCure MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.90 ➝ $2.903/20/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.003/5/2024ICCMIceCure MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00(Data available from 4/20/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$2.07M59.85N/AN/A$0.72 per share6.76GBSGBS$440K92.72N/AN/A$0.44 per share6.23ICCMIceCure Medical$3.23M17.09N/AN/A$0.27 per share4.48NVNOenVVeno MedicalN/AN/AN/AN/A$3.47 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)GBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/AICCMIceCure Medical-$14.65M-$0.33N/AN/AN/A-453.76%-86.96%-68.63%5/27/2024 (Estimated)NVNOenVVeno Medical-$23.52M-$1.92N/AN/AN/AN/A-70.17%-64.68%5/6/2024 (Estimated)Latest DCTH, GBS, NVNO, and ICCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/3/2024Q4 2023ICCMIceCure Medical-$0.08-$0.07+$0.01-$0.07N/A$1.26 million 3/26/2024Q4 23DCTHDelcath Systems-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million 2/29/2024Q4 2023NVNOenVVeno MedicalN/A-$0.32-$0.32-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/AGBSGBSN/AN/AN/AN/AN/AICCMIceCure MedicalN/AN/AN/AN/AN/ANVNOenVVeno MedicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A2.262.06GBSGBSN/A2.332.33ICCMIceCure Medical0.033.663.08NVNOenVVeno MedicalN/A34.2234.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%GBSGBS2.79%ICCMIceCure Medical0.62%NVNOenVVeno Medical34.71%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems21.10%GBSGBS0.27%ICCMIceCure Medical2.44%NVNOenVVeno Medical17.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems7625.44 million20.07 millionOptionableGBSGBS714.89 million14.85 millionNot OptionableICCMIceCure Medical6545.62 million44.51 millionNot OptionableNVNOenVVeno Medical1913.32 million11.05 millionOptionableDCTH, GBS, NVNO, and ICCM HeadlinesSourceHeadlineNew Topline Efficacy Data from the enVVeno Medical…pharmiweb.com - April 16 at 1:05 PMNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024finance.yahoo.com - April 16 at 1:05 PMenVVeno Medical hires new CCO to guide transitionuk.investing.com - April 11 at 9:42 AMenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinanznachrichten.de - April 10 at 4:14 AMenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officerfinance.yahoo.com - April 9 at 12:21 PMenVVeno Medical Corporation (NASDAQ:NVNO) CTO Hamed Alavi Sells 8,334 Sharesinsidertrades.com - March 16 at 10:58 AMNVNO Apr 2024 10.000 callfinance.yahoo.com - March 16 at 2:23 AMenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunityfinance.yahoo.com - March 15 at 11:16 AMPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meetingfinance.yahoo.com - March 6 at 5:49 PMCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growthfinance.yahoo.com - March 3 at 11:28 AMenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 29 at 8:20 PMRecap: enVVeno Medical Q4 Earningsbenzinga.com - February 29 at 8:20 PMenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 29 at 8:20 PMTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024finance.yahoo.com - February 20 at 10:08 AMenVVeno Medical Corporation's (NASDAQ:NVNO) Path To Profitabilityfinance.yahoo.com - January 6 at 9:49 AMNVNO Jan 2024 5.000 callca.finance.yahoo.com - December 29 at 4:00 PMenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinanznachrichten.de - December 14 at 12:07 PMenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposiumfinance.yahoo.com - December 14 at 12:07 PMenVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposiumfinance.yahoo.com - November 16 at 9:45 AMenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinanznachrichten.de - October 26 at 8:13 PMenVVeno Medical files to sell 14.71M shares for holdersmsn.com - October 26 at 8:13 PMenVVeno Medical reports Q3 resultsmsn.com - October 26 at 3:10 PMenVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - October 26 at 8:22 AMenVVeno Medical to Participate at the Virtual Investor Ask the CEO Conferencefinance.yahoo.com - October 12 at 1:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDelcath SystemsNASDAQ:DCTHDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.GBSNYSE:GBSGBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.IceCure MedicalNASDAQ:ICCMIceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.enVVeno MedicalNASDAQ:NVNOenVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.